Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCTH
3051
DELISTED
Delcath Systems Inc
DCTH
| $147K | ﹤0.01% |
160,128
+100,214
| +167% | +$194K |
|
3052
Maui Land & Pineapple Co
MLP
$310M
| $146K | ﹤0.01% |
20,300
+2,629
| +15% | +$17.9K |
|
3053
Halozyme
HALO
$11.4B
| $145K | ﹤0.01% |
14,700
-85,300
| -85% | -$934K |
|
|
PW
3054
Power REIT
PW
$2.93M
| $145K | ﹤0.01% |
2,060
+250
| +14% | +$20.2K |
|
|
CASI
3055
DELISTED
CASI Pharmaceuticals
CASI
| $144K | ﹤0.01% |
12,480
+6,350
| +104% | +$86.9K |
|
3056
Marathon Digital Holdings
MARA
$3.56B
| $144K | ﹤0.01% |
5,250
+3,806
| +264% | +$125K |
|
3057
ImmunityBio
IBRX
$8.11B
| $140K | ﹤0.01% |
+24,500
| New | +$163K |
|
|
STLY
3058
DELISTED
Stanley Furniture Co Inc
STLY
| $140K | ﹤0.01% |
156,000
+19,556
| +14% | +$24.1K |
|
|
FNJN
3059
DELISTED
Finjan Holdings, Inc.
FNJN
| $138K | ﹤0.01% |
122,200
+13,700
| +13% | +$18.8K |
|
3060
ReWalk Robotics
LFWD
$22.2M
| $136K | ﹤0.01% |
23
+14
| +156% | +$107K |
|
3061
Global Net Lease
GNL
$1.9B
| $132K | ﹤0.01% |
5,600
-36,600
| -87% | -$838K |
|
|
NHLD
3062
DELISTED
National Holdings Corporation
NHLD
| $132K | ﹤0.01% |
49,200
-70,900
| -59% | -$223K |
|
|
HTGM
3063
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $130K | ﹤0.01% |
323
+79
| +32% | +$31.5K |
|
3064
Atossa Therapeutics
ATOS
$25.5M
| $128K | ﹤0.01% |
505
+275
| +120% | +$85.7K |
|
|
ECYT
3065
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $128K | ﹤0.01% |
50,100
-138,900
| -73% | -$399K |
|
|
YGE
3066
DELISTED
Yingli Green Energy Holding Comp
YGE
| $128K | ﹤0.01% |
49,389
+20,400
| +70% | +$70.3K |
|
|
SVT
3067
DELISTED
Servotronics
SVT
| $127K | ﹤0.01% |
+12,600
| New | +$131K |
|
3068
Savara
SVRA
$1.08B
| $126K | ﹤0.01% |
20,697
+746
| +4% | +$4.69K |
|
|
BYBK
3069
DELISTED
Bay Bancorp, Inc.
BYBK
| $126K | ﹤0.01% |
+19,100
| New | +$112K |
|
|
PGLC
3070
DELISTED
Pershing Gold Corporation. Common Stock
PGLC
| $126K | ﹤0.01% |
38,400
-244,400
| -86% | -$949K |
|
3071
Stabilis Solutions
SLNG
$104M
| $125K | ﹤0.01% |
10,088
+488
| +5% | +$7.41K |
|
|
SUNW
3072
DELISTED
Sunworks, Inc.
SUNW
| $125K | ﹤0.01% |
+8,924
| New | +$158K |
|
3073
Enlivex Ltd
ENLV
$28.4M
| $124K | ﹤0.01% |
198
+57
| +40% | +$48.3K |
|
|
BLPH
3074
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $124K | ﹤0.01% |
15,940
+12,240
| +331% | +$170K |
|
|
RLOG
3075
DELISTED
Rand Logistics, Inc.
RLOG
| $124K | ﹤0.01% |
149,600
+10,000
| +7% | +$8.54K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.